Alpha-Melanocyte-Stimulating Hormone (α-MSH)
Also known as: α-MSH, alpha-MSH, Alpha-melanotropin, Melanotropin, α-melanocortin
Neuropeptide / Melanocortin peptide (tridecapeptide derived from pro-opiomelanocortin [POMC])
What it is
Researchers study Alpha-Melanocyte-Stimulating Hormone (α-MSH) for its role in inflammation, appetite regulation, skin pigmentation, and cartilage protection. It activates receptors that help regulate the immune response and energy balance throughout the body. No FDA-approved therapeutic use; evidence comes primarily from animal and cell studies.
The scientific side
α-MSH is a 13 amino acid neuropeptide derived by intracellular cleavage of pro-opiomelanocortin (POMC). It acts at melanocortin receptors (MCRs), a family of G-protein-coupled receptors; the melanocortin-1 receptor (MC1-R) is primarily involved in regulation of skin pigmentation and is expressed on melanocytes and melanoma cells. The MC4 receptor has been most closely linked to body weight regulation, where α-MSH acts as an anorexigenic signal after central injection. Activation of POMC neurons increases α-MSH production, inhibiting orexigenic signals. α-MSH also has potent anti-inflammatory activity, modulates immune cell function including macrophage activity, and participates in regulation of sympathetic nervous system activity. In the ocular microenvironment, α-MSH (together with NPY) suppresses phagosome maturation in macrophages and promotes immune privilege.
Class: Neuropeptide / Melanocortin peptide (tridecapeptide derived from pro-opiomelanocortin [POMC])
Administration & storage
- Administration
- Subcutaneous injection of α-MSH analogues (Melanotan-I/II) reported by survey respondents (PMID: 30142729)Intracranial/intrahypothalamic injection into medial preoptic area in animal studies (PMID: 2671829)In vitro perifusion of neurointermediate lobe tissue (PMID: 21554663)In vitro perifusion of rat hypothalamic slices (PMID: 1698247)
- Storage
- No abstracts in the reviewed literature describe storage conditions for α-MSH.
- Cautions
- Development of multiple new atypical naevi reported within one week of subcutaneous injection of a Melanotan (α-MSH analogue), raising concern for risk of stimulating dysplastic naevi or malignant melanoma.,Melanotan-I and Melanotan-II are α-MSH analogues purchased and injected illicitly without regulatory oversight; purity and safety of unregulated internet-sourced substances are unknown.,No human pharmacokinetic or safety data for α-MSH itself (as distinct from synthetic analogues) are available in the reviewed literature.,Sterile technique is essential for any injectable peptide to prevent contamination and infection.,No approved dosing, reconstitution, or administration protocol for α-MSH has been described in the reviewed literature.
Legal & regulatory status
Not stated in reviewed literature — requires manual verification
Not stated in reviewed literature — requires manual verification
Not stated in reviewed literature — requires manual verification
What it's studied for
- Anti-inflammatory / immunomodulatory effects Mixed
- Review examining α-MSH and related peptides as modulators of fever and inflammation, noting promising targets in inflammatory disorders. Synthetic melanocortins with selective affinities for specific MCRs could form new classes of therapeutic molecules. PMID 16437015 Catania et al., Pediatric Endocrinology Reviews (2003)
- In human monocytic THP-1 cells, α-MSH significantly inhibited IFN-γ/TNF-α-stimulated neopterin production, suggesting an autocrine regulatory circuit based on α-MSH in human monocyte/macrophages. PMID 8603997 Rajora et al., Journal of Leukocyte Biology (1996)
- α-MSH co-treatment with NPY suppressed phagosome maturation in macrophages (reduced Rab7 recruitment, suppressed LAMP1 expression) and suppressed Ag-stimulated CD4 T cell proliferation in vitro, suggesting a mechanism of ocular immune privilege. PMID 30613828 Benque et al., ImmunoHorizons (2018)
- Regulation of appetite, body weight, and energy balance Mixed
- Review: α-MSH acts at MC4R in the hypothalamus to suppress appetite after central injection. Evidence from murine and human genetic models of disrupted melanocortin signalling firmly established a central role for POMC-expressing hypothalamic neurons in controlling appetite and body weight. PMID 10623776 Yeo et al., QJM (2000)
- Review: Activation of POMC neurons increases α-MSH production and inhibits release of NPY and AgRP. α-MSH and NPY appear implicated in hypothalamic regulation of sympathetic nervous system activity and may contribute to hypertension in obesity. PMID 18793378 Baltatzi et al., International Journal of Clinical Practice (2008)
- Serum α-MSH levels were significantly lower in children with Prader-Willi syndrome (PWS) and Bardet-Biedl syndrome (BBS) compared to obese and lean controls (PWS: 3729 ± 1319 pg/ml; BBS: 4543 ± 658 pg/ml; obese controls: 5211 ± 829 pg/ml; lean controls: 5681 ± 565 pg/ml, p<0.001). Authors speculate serum α-MSH may be a PMID 35098494 Turkkahraman et al., Journal of Endocrinological Investigation (2022)
- Pilot study (n=160): Plasma α-MSH levels were similar across all groups (obese, overweight, normal weight; hypertensive and normotensive), in contrast to NPY which varied significantly. Role of α-MSH in obesity-related hypertension not confirmed in this study. PMID 22254185 Baltazi et al., American Journal of Cardiovascular Disease (2011)
- Melanoma imaging and targeted radionuclide therapy Animal studies only
- Preclinical review: Radiolabeled α-MSH analogues demonstrated low-to-subnanomolar affinities for MC1-R in vitro. In B16 mouse melanoma models, cyclic α-MSH analogues showed rapid tumor uptake and prolonged retention. Cyclic α-MSH analogues labeled with beta and alpha emitting radionuclides demonstrated melanoma therape PMID 20467398 Quinn et al., Giornale italiano di dermatologia e venereologia (2010)
- Cartilage protection / anti-inflammatory in joint disease Human observational
- In 51 patients with ACL deficiency, synovial fluid α-MSH levels were inversely correlated with Noyes scores (r = -0.682, p<0.001), IL-6 (r = -0.302, p=0.035), MMP-3 (r = -0.652, p<0.001), and CTX-II (r = -0.584, p<0.001). Authors suggest α-MSH supplementation may serve as adjuvant therapy for delaying cartilage degener PMID 26427140 Liu et al., Clinical Laboratory (2015)
- Hepatoprotection Animal studies only
- In male CBA mice, α-MSH demonstrated hepatoprotective effects (assessed by liver enzyme levels) in an acetaminophen-induced liver injury model. The antisense peptide LVKAT abolished these hepatoprotective effects of α-MSH in vivo. PMID 21873934 Houra et al., Molecules (2011)
- Sexual function / SSRI-induced sexual dysfunction Human observational
- In a study of 92 patients and 49 healthy volunteers, α-MSH and MC4R levels were significantly lower in patients with SSRI-related sexual dysfunction compared to controls and non-dysfunctional SSRI users. Authors suggest serotonin may mediate sexual dysfunction via α-MSH and MC4R through 5-HT2C antagonism. Limitations i PMID 39712869 Kurt Kaya et al., Sexual Medicine (2024)
- Melanogenesis stimulation (tanning) Human observational
- Observational survey of online forum users: Melanotan-I and Melanotan-II, α-MSH analogues, are injected subcutaneously by users to stimulate tanning. These are unregulated substances purchased illicitly online. PMID 30142729 Callaghan, Dermatology Online Journal (2018)
- Case report: A patient developed multiple new-onset atypical naevi within one week of receiving two Melanotan (α-MSH analogue) injections, highlighting potential risk of stimulating dysplastic naevi or possibly malignant melanoma. PMID 23914578 Reid et al., Irish Medical Journal (2013)
- Endodontic/pulp tissue regeneration (anti-inflammatory biomaterial component) In vitro only
- In vitro: α-MSH coupled to Poly-Glutamic Acid (PGA) incorporated into multilayered films increased the anti-inflammatory reaction of pulp fibroblasts and macrophages stimulated by LPS. Nanostructured assemblies (DGLG4-PGA-α-MSH)n promoted adhesion and proliferation of pulp fibroblasts on biomaterial surface. PMID 21830492 Fioretti et al., Journal of Biomedical Nanotechnology (2011)
- Melanogenesis inhibition research (used as stimulus in anti-pigmentation studies) Animal studies only
- α-MSH was used to stimulate melanogenesis in B16F10 murine melanoma cells and zebrafish models to test anti-melanogenic compounds. α-MSH stimulated tyrosinase activity, melanin content, CREB phosphorylation, and MITF expression via PKA/CREB and ERK pathways. PMID 33474761 Ding et al., Cell Biochemistry and Function (2021)
- α-MSH induced differentiation in B16 melanoma cells characterized by increased melanin biosynthesis. Calpain activity was decreased within 2 h following α-MSH treatment. Calpain inhibitors blocked α-MSH-induced melanogenesis. PMID 16335789 Ohguchi et al., Molecular and Cellular Biochemistry (2005)
- Male sexual behavior facilitation (animal studies) Animal studies only
- Review: Injections of α-MSH directly into the medial preoptic area of male rats can facilitate sexual behavior. α-MSH is listed among stimulatory neuropeptides in the context of male sexual behavior. PMID 2671829 Dornan & Malsbury, Neuroscience and Biobehavioral Reviews (1989)
- Prolactin release from anterior pituitary Animal studies only
- The hypophysiotropic signal mediating massive discharge of anterior pituitary prolactin appears to derive from the neurointermediate lobe (NIL), and a major component of this signal appears to be α-MSH. PMID 18407195 Frawley, Trends in Endocrinology and Metabolism (1994)
Safety signals
- Development of multiple new atypical (dysplastic) naevi within one week of subcutaneous injection of a Melanotan (α-MSH analogue), with concern for possible risk of stimulating malignant melanoma PMID 23914578
- Illicit online market for α-MSH analogues (Melanotan-I and Melanotan-II) with subcutaneous self-injection; substances are unregulated with unknown purity and safety profile PMID 30142729
Contraindications
- No formal contraindications for α-MSH administration in humans are described in the reviewed literature. Use of unregulated α-MSH analogues in individuals with pre-existing melanocytic lesions or melanoma risk may be particularly hazardous based on case report evidence. PMID 23914578
Protocol
500 mcg subcutaneous injection, once daily. Cycle: 2-4 weeks.
About these dose ranges
Dose ranges below reflect commonly reported community protocols. Where published research cites a specific dose, the PMID is linked. Doses without citations are not clinical recommendations — they reflect what practitioners and researchers commonly report using.
Community-reported dosing
| Route | Dose | Frequency / Duration | Population / context | Source tier |
|---|---|---|---|---|
| In vitro perifusion (neurointermediate lobe of frog pituitary) | 10⁻⁹ to 10⁻⁴ M (graded doses) | Acute perifusion experiments | in_vitro | Research PMID 44711 |
| In vitro perifusion (rat hypothalamic slices) | 50 mM K+ (as stimulus control comparator); veratridine 50 µM and ouabain 1 mM used as stimuli; α-MSH release measured from perifused rat hypothalamic slices | Acute in vitro experiments | in_vitro | Research PMID 1698247 |
| Not stated (in vivo mouse study) | Not explicitly stated (dose of α-MSH administered to mice not specified in abstract) | Not stated | animal | Research PMID 21873934 |
| In vitro cell culture | α-MSH used as a stimulus in cell culture; specific concentration not stated in abstract | Not stated | in_vitro | Research PMID 33474761 |
| In vitro cell culture | α-MSH used as a stimulus in B16 melanoma cells; specific concentration not stated in abstract | Not stated | in_vitro | Research PMID 16335789 |
| subcutaneous injection | 500 mcg | once daily · 2-4 weeks | biohackers and peptide community users experimenting with melanocortin system modulation | [Community] |
| subcutaneous injection | 250 mcg | once daily · 2-4 weeks | peptide community beginners or those sensitive to melanocortin side effects (nausea, flushing) | [Community] |
| subcutaneous injection | 250 mcg | twice daily · 1-3 weeks | intermediate peptide users seeking sustained melanocortin receptor occupancy throughout the day | [Community] |
| subcutaneous injection | 1000 mcg | once daily · 1-2 weeks | experienced biohackers pushing higher melanocortin receptor saturation; less commonly reported | [Community] |
| intranasal | 500 mcg | once daily · 2-4 weeks | biohackers preferring needle-free administration; users interested in CNS/appetite effects via intranasal route | [Community] |
All studies (21)
- PMID 23914578 Human observational
Melanogenesis stimulation (tanning) - PMID 26427140 Human observational
Cartilage protection / anti-inflammatory in joint disease - PMID 30142729 Human observational
Melanogenesis stimulation (tanning) - PMID 39712869 Human observational
Sexual function / SSRI-induced sexual dysfunction - PMID 8603997 Mixed
Anti-inflammatory / immunomodulatory effects - PMID 10623776 Mixed
Regulation of appetite, body weight, and energy balance - PMID 16437015 Mixed
Anti-inflammatory / immunomodulatory effects - PMID 18793378 Mixed
Regulation of appetite, body weight, and energy balance - PMID 22254185 Mixed
Regulation of appetite, body weight, and energy balance - PMID 30613828 Mixed
Anti-inflammatory / immunomodulatory effects - PMID 35098494 Mixed
Regulation of appetite, body weight, and energy balance - PMID 44711
10⁻⁹ to 10⁻⁴ M (graded doses) In vitro perifusion (neurointermediate lobe of frog pituitary) (in_vitro) - PMID 1698247
50 mM K+ (as stimulus control comparator); veratridine 50 µM and ouabain 1 mM used as stimuli; α-MSH release measured from perifused rat hypothalamic slices In - PMID 2671829 Animal studies only
Male sexual behavior facilitation (animal studies) - PMID 16335789 Animal studies only
Melanogenesis inhibition research (used as stimulus in anti-pigmentation studies) - PMID 18407195 Animal studies only
Prolactin release from anterior pituitary - PMID 20467398 Animal studies only
Melanoma imaging and targeted radionuclide therapy - PMID 21554663
- PMID 21830492 In vitro only
Endodontic/pulp tissue regeneration (anti-inflammatory biomaterial component) - PMID 21873934 Animal studies only
Hepatoprotection - PMID 33474761 Animal studies only
Melanogenesis inhibition research (used as stimulus in anti-pigmentation studies)
Frequently asked
What is α-MSH and what does it do in the body?
α-MSH (alpha-melanocyte-stimulating hormone) is a 13 amino acid neuropeptide derived from pro-opiomelanocortin (POMC). It acts at melanocortin receptors (G-protein-coupled receptors). Key roles documented in the reviewed literature include: regulation of skin pigmentation via MC1-R on melanocytes; suppression of appetite and body weight regulation via hypothalamic MC4R; anti-inflammatory and immunomodulatory effects in macrophages and monocytes (PMID 16437015, PMID 8603997); and suppression of phagosome maturation in ocular immune privilege.
Can α-MSH help with weight loss?
Research in murine and human genetic models has established that hypothalamic POMC-derived α-MSH, acting at the MC4 receptor, suppresses appetite after central injection. In children with Prader-Willi syndrome and Bardet-Biedl syndrome — conditions associated with obesity — serum α-MSH levels were significantly lower than in lean or obese controls. However, a pilot study of 160 adults found plasma α-MSH levels were similar across obese, overweight, and normal-weight groups. No human clinical trials of α-MSH administration for weight loss were identified in the reviewed literature. I can't recommend a protocol — please consult a licensed healthcare provider.
What dose of α-MSH should I take?
I'm not a medical professional and can't recommend a protocol for you specifically. What research has shown: The reviewed literature does not include human clinical trials establishing safe or effective doses of α-MSH for any indication. The only human-related dosing context involves illicit subcutaneous use of α-MSH analogues (Melanotan) for tanning, which are unregulated substances of unknown purity.
Is α-MSH (or Melanotan) safe to inject for tanning?
The reviewed literature raises significant safety concerns. A case report documented development of multiple new atypical naevi within one week of two Melanotan (α-MSH analogue) subcutaneous injections, with concern for possible risk of stimulating dysplastic naevi or malignant melanoma. Melanotan products are purchased illicitly online and are unregulated substances of unknown purity. No approved dosing or safety profile exists in the reviewed published literature. Please speak with a licensed healthcare provider before considering any use.
Can I stack α-MSH with other peptides or compounds?
I can't recommend combining compounds — that's a prescribing decision. Here's what has been studied individually: α-MSH has been studied in combination with NPY (neuropeptide Y) in an in vitro ocular immunity context, and its interactions with leptin, NPY, and AgRP have been reviewed in the context of obesity and hypertension. No human combination protocols are described in the reviewed literature.
Does α-MSH have anti-inflammatory effects?
Yes, anti-inflammatory effects of α-MSH are documented in the reviewed literature. In vitro studies show that α-MSH inhibited neopterin production (a marker of immune activation) in human monocytic THP-1 cells stimulated with IFN-γ and TNF-α. α-MSH with NPY suppressed phagosome maturation in macrophages in vitro. A review identified promising targets for α-MSH in inflammatory disorders via melanocortin receptors. In an in vitro dental pulp model, α-MSH coupled to a polymer carrier increased anti-inflammatory responses of pulp fibroblasts and macrophages. These are largely preclinical findings; no human clinical trials of α-MSH for inflammation were identified in the reviewed literature.
What is the relationship between α-MSH and sexual function?
Animal studies report that injection of α-MSH directly into the medial preoptic area can facilitate male sexual behavior in rats. In a human observational study (n=92 patients, 49 controls), α-MSH and MC4R levels were significantly lower in female patients with SSRI-related sexual dysfunction compared to controls, suggesting a possible role in SSRI-induced sexual dysfunction. The authors note this is the first human study in this field, and limitations include small sample size and unknown baseline levels. I can't suggest treatments for medical conditions. Please speak with a licensed healthcare provider.
Is α-MSH or Melanotan legal to buy or use?
The reviewed literature does not explicitly state the regulatory status of α-MSH or Melanotan under FDA, Health Canada, or WADA rules. The literature does describe Melanotan (an α-MSH analogue) as being purchased illicitly online and notes it is an unregulated substance. Manual verification of current regulatory status is required. I don't recommend vendors or sources. Please consult a licensed provider.
What are the risks of using Melanotan for tanning?
The reviewed literature documents: (1) Development of multiple new atypical naevi within one week of two Melanotan injections in one case report patient, raising concern for stimulation of dysplastic naevi or possibly malignant melanoma; (2) Melanotan products are unregulated substances sold illicitly online with unknown purity and safety. No systematic human safety studies of Melanotan or α-MSH are available in the reviewed literature. Please speak with a licensed healthcare provider.
Can α-MSH protect cartilage or joints?
An observational study in 51 patients with anterior cruciate ligament (ACL) deficiency found that synovial fluid α-MSH levels were inversely correlated with articular cartilage degeneration (Noyes score r = -0.682, p<0.001) and with inflammatory markers IL-6, MMP-3, and CTX-II. The authors speculate that α-MSH supplementation may serve as a possible adjuvant therapy for delaying cartilage degeneration after ACL injury, but no human interventional trials are available in the reviewed literature. I can't suggest treatments for medical conditions. Please speak with a licensed healthcare provider.